Filtered By:
Condition: Polyps
Cancer: Nasal Cavity and Paranasal Sinus Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3 results found since Jan 2013.
FDA approves Xolair ® (omalizumab) for adults with nasal polyps
Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news
Nasal Polyps and Future Risk of Head and Neck Cancer: A Nationwide Population-based Cohort Study
Nasal polyps were associated with increased risks of nasal cavity and paranasal sinus or nasopharyngeal cancers, particularly among older adults.
Source: Journal of Allergy and Clinical Immunology - July 2, 2019 Category: Allergy & Immunology Authors: Hyun Jung Kim, Hyeong Sik Ahn, Taeuk Kang, Claus Bachert, Woo-Jung Song Source Type: research
